  |
| This newsletter is brought
to you by Confederation of Indian Industry - Technology & IPR Department. |
| View Point From the Technology & IPR Desk CII Technology Division
starts handling Biotechnology and Pharma sectors. Recent news reports indicate that India can be a good option for clinical trials, as the cost associated with it is perceived to be 20-30% lesser. There is also a good mix of genes, so that the medicines can be effectively tested. On the other side, health care sector is proving to be a large market. MNC are investing to capture the market in their niche areas. Meanwhile, there is lot of burning issues to be resolved in the best interest of the nation. All these things sets a stage for exciting time ahead… - From the Technology Desk ll the views expressed in the article are personal and do not necessarily reflect the views of the organization the author represents. |
General 
|
|
IPR
|
|
|
Nanotechnology
|
|
|
Electronics, Communication and Instrumentation
|
|
Energy & Environment
|
|
IT & Software
|
|
Pharma, Biotech and Health
|
|